Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRT018
MIFTS: 50

Portal Vein Thrombosis

Categories: Blood diseases, Cardiovascular diseases, Endocrine diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Portal Vein Thrombosis

About this section

MalaCards integrated aliases for Portal Vein Thrombosis:

Name: Portal Vein Thrombosis 12 76 29 55 15 73

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Endocrine diseases Gastrointestinal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11695
ICD10 33 I81
ICD9CM 35 452
NCIt 50 C78565
SNOMED-CT 68 17920008
UMLS 73 C0155773
Sources

Summaries for Portal Vein Thrombosis

About this section
Disease Ontology : 12 A vein disease that is characterized by a blood clot that forms within the hepatic portal vein.

MalaCards based summary : Portal Vein Thrombosis is related to liver cirrhosis and thrombosis. An important gene associated with Portal Vein Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs tannic acid and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone, and related phenotypes are homeostasis/metabolism and integument

Wikipedia : 76 Portal vein thrombosis is a form of venous thrombosis affecting the hepatic portal vein, which can lead... more...

Sources

Related Diseases for Portal Vein Thrombosis

About this section

Diseases related to Portal Vein Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 liver cirrhosis 31.1 AFP F2 SERPINC1
2 thrombosis 30.5 APOH F2 F5 F7 JAK2 MTHFR
3 protein c deficiency 30.3 F2 F5 MTHFR SERPINC1
4 purpura 30.3 APOH F2 SERPINC1
5 hypersplenism 30.3 F2 SERPINC1
6 varicose veins 30.2 F2 F5 MTHFR SERPINC1
7 thrombocytosis 30.1 F2 JAK2 SELP SERPINC1
8 protein s deficiency 30.0 APOH F2 F5 MTHFR SERPINC1
9 polycythemia vera 30.0 F5 JAK2 SELP
10 homocysteinemia 30.0 F2 F5 MTHFR SERPINC1
11 budd-chiari syndrome 30.0 APOH F2 F5 F7 JAK2 MTHFR
12 lemierre's syndrome 30.0 MTHFR SERPINE1
13 eclampsia 30.0 F2 MTHFR SERPINC1
14 homocystinuria 29.9 F5 MTHFR SERPINC1
15 hepatic infarction 29.9 APOH F2 MTHFR SERPINC1
16 hemophilia 29.9 F2 F7
17 hepatic veno-occlusive disease 29.9 SERPINC1 SERPINE1
18 antithrombin iii deficiency 29.9 APOH F2 F5 MTHFR SERPINC1
19 esophageal varix 29.8 AFP F2 SERPINC1
20 thrombophilia 29.8 APOH F2 F5 MTHFR SERPINC1 SERPINE1
21 hemophilia a 29.8 F5 F7
22 essential thrombocythemia 29.8 F2 JAK2 SELP SERPINE1
23 acute myocardial infarction 29.7 SELP SERPINC1 SERPINE1
24 antiphospholipid syndrome 29.6 APOH F2 F5 MTHFR SELP SERPINC1
25 disseminated intravascular coagulation 29.5 F2 F5 F7 SERPINC1 SERPINE1
26 thrombophilia due to thrombin defect 29.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
27 pulmonary embolism 29.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
28 ischemic colitis 29.5 APOH F2 F5 SERPINC1 SERPINE1
29 cerebrovascular disease 29.0 F2 F5 F7 MTHFR SELP SERPINE1
30 myocardial infarction 29.0 F2 F5 F7 MTHFR SELP SERPINC1
31 stroke, ischemic 28.7 APOH F2 F5 F7 MTHFR SELP
32 pre-eclampsia 28.6 AFP APOH F2 F5 MTHFR SELP
33 primitive portal vein thrombosis 12.7
34 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.2
35 hepatocellular carcinoma 10.9
36 portal hypertension 10.6
37 liver disease 10.5
38 hepatitis 10.5
39 pancreatitis 10.4
40 colitis 10.3
41 thalassemia 10.3
42 ulcerative colitis 10.3
43 cholecystitis 10.3
44 acute pancreatitis 10.3
45 cytomegalovirus infection 10.3
46 hepatitis b 10.2
47 hepatitis c 10.2
48 banti's syndrome 10.2
49 encephalopathy 10.2
50 paracetamol poisoning 10.2 F2 F5

Comorbidity relations with Portal Vein Thrombosis via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Vascular Insufficiency of Intestine
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Portal Vein Thrombosis:



Diseases related to Portal Vein Thrombosis
Sources

Symptoms & Phenotypes for Portal Vein Thrombosis

About this section

MGI Mouse Phenotypes related to Portal Vein Thrombosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 AFP APOH F2 F5 F7 JAK2
2 integument MP:0010771 9.63 F2 F5 JAK2 MTHFR SELP SERPINE1
3 liver/biliary system MP:0005370 9.5 AFP F5 JAK2 MTHFR SELP SERPINC1
4 mortality/aging MP:0010768 9.32 AFP APOH F2 F5 F7 JAK2
Sources

Drugs & Therapeutics for Portal Vein Thrombosis

About this section

Drugs for Portal Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 tannic acid Approved Phase 4,Not Applicable
2
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 6691 54678486
3
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
4
Nadroparin Approved, Investigational Phase 4,Not Applicable
5
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
6
Dipyridamole Approved Phase 4 58-32-2 3108
7
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
10
Ethiodized oil Approved, Investigational Phase 4,Not Applicable 8008-53-5
11
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
12 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
13 Bone Density Conservation Agents Phase 4,Not Applicable
14 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Calcium, Dietary Phase 4,Phase 2,Not Applicable
16 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
19 Analgesics Phase 4,Phase 1,Phase 2
20 Phosphodiesterase Inhibitors Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
22 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
23 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
24 Antirheumatic Agents Phase 4,Phase 1,Phase 2
25 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4
27 Antipyretics Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
29 Heparin, Low-Molecular-Weight Phase 4,Phase 3,Phase 2,Not Applicable
30 Platelet Aggregation Inhibitors Phase 4,Phase 2
31 Pharmaceutical Solutions Phase 4,Phase 3
32 Hypolipidemic Agents Phase 4,Phase 3
33 Glucuronyl glucosamine glycan sulfate Phase 4
34 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
35 Lipid Regulating Agents Phase 4,Phase 3
36 insulin Phase 4
37 Insulin, Globin Zinc Phase 4
38
Propranolol Approved, Investigational Phase 3,Not Applicable 525-66-6 4946
39
Norfloxacin Approved Phase 3 70458-96-7 4539
40
Simvastatin Approved Phase 3 79902-63-9 54454
41
Rivaroxaban Approved Phase 3,Not Applicable 366789-02-8
42
Enoxaparin Approved Phase 3,Phase 2,Not Applicable 9005-49-6 772
43
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
44
Apixaban Approved Phase 3 503612-47-3 10182969
45
Serine Approved, Nutraceutical Phase 3,Not Applicable 56-45-1 5951
46 Anti-Arrhythmia Agents Phase 3,Not Applicable
47 Antihypertensive Agents Phase 3,Not Applicable
48 Adrenergic Agents Phase 3,Not Applicable
49 Adrenergic Antagonists Phase 3,Not Applicable
50 Adrenergic beta-Antagonists Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
2 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
3 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
4 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
5 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
6 Intraoperative Glucose Control in Liver Transplant Completed NCT00780026 Phase 4 insulin
7 Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
8 TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV Unknown status NCT02853526 Phase 3 Propranolol;Warfarin
9 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
10 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
11 Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver Cirrhosis Unknown status NCT01421550 Phase 3
12 Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Completed NCT02250391 Phase 3 NPB-06;Placebo
13 Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Completed NCT01095185 Phase 3 Simvastatin;Placebo
14 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis Recruiting NCT03193502 Phase 3 rivaroxaban
15 Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study Recruiting NCT02627053 Phase 3 rivaroxaban
16 Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis Recruiting NCT02643212 Phase 3 Rivaroxaban;Placebo
17 Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation Recruiting NCT02584283 Phase 3 Glutathione
18 Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Active, not recruiting NCT02555111 Phase 3 Xarelto
19 Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients Active, not recruiting NCT02802605 Phase 3 Bemiparin
20 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Active, not recruiting NCT02585713 Phase 3 Apixaban;Dalteparin
21 Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Not yet recruiting NCT02715492 Phase 3 LMWH
22 Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients Suspended NCT02271295 Phase 3 Enoxaparine
23 Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein Terminated NCT01887717 Phase 3 Sorafenib
24 TIPS or Anticoagulation in Portal Vein Thrombosis Withdrawn NCT03422419 Phase 3 Heparin
25 Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein Completed NCT02367534 Phase 1, Phase 2
26 Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma Completed NCT00910572 Phase 2
27 Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression Completed NCT00566813 Phase 1, Phase 2 Islet Cell Transplant;Islet Cell Transplant plus
28 Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients Completed NCT01636778 Phase 2 SB-497115-GR
29 Complement Inhibitor Eculizumab in Clinical Islet Transplantation Completed NCT02727608 Phase 2 Eculizumab
30 Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis Recruiting NCT03009461 Phase 2 Sorafenib
31 Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy Recruiting NCT02390713 Phase 1, Phase 2
32 Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma Recruiting NCT03535259 Phase 2
33 Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION) Active, not recruiting NCT02350218 Phase 2 Eglandin
34 Islet Transplant in Patients With Type I Diabetes Not yet recruiting NCT03698396 Phase 1, Phase 2
35 Anticoagulation Post Laparoscopic Splenectomy Terminated NCT00769873 Phase 2 Enoxaparin
36 Safety Study of Autologous Stem Cell in Liver Cirrhosis Terminated NCT00382278 Phase 1, Phase 2
37 The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC Recruiting NCT02814461 Phase 1 Axitinib
38 Islet Allotransplantation in Type 1 Diabetes Enrolling by invitation NCT01705899 Phase 1 Human Pancreatic Islets
39 Reversible Portal Vein Embolization Before Major Hepatectomy Not yet recruiting NCT02945059 Phase 1
40 Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt Unknown status NCT03031717
41 Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study. Unknown status NCT02597218
42 Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy Unknown status NCT02066974
43 A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction Unknown status NCT02659852 Not Applicable
44 Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding Unknown status NCT02964195 Not Applicable Rifaximin
45 Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy Unknown status NCT01549795 Not Applicable Capecitabine
46 Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis Completed NCT02069457
47 Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV Completed NCT03201367 Not Applicable Rivaroxaban
48 TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis Completed NCT01556282 Not Applicable
49 Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry Completed NCT01470547
50 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis Completed NCT01326949 Not Applicable

Search NIH Clinical Center for Portal Vein Thrombosis

Sources

Genetic Tests for Portal Vein Thrombosis

About this section

Genetic tests related to Portal Vein Thrombosis:

# Genetic test Affiliating Genes
1 Portal Vein Thrombosis 29
Sources

Anatomical Context for Portal Vein Thrombosis

About this section

MalaCards organs/tissues related to Portal Vein Thrombosis:

41
Liver, Spleen, Bone, Pancreatic Islet, Myeloid, Pancreas, Heart
Sources

Publications for Portal Vein Thrombosis

About this section

Articles related to Portal Vein Thrombosis:

(show top 50) (show all 1057)
# Title Authors Year
1
Retrospective study of the incidence of portal vein thrombosis after splenectomy in hematological disorders: Risk factors and clinical presentation. ( 30293687 )
2019
2
Characterization of Malignant Portal Vein Thrombosis with Contrast-Enhanced Ultrasonography. ( 30366607 )
2019
3
Percutaneous extrahepatic splenomeso-caval shunt creation in a patient with portal vein thrombosis after Whipple procedure. ( 30445372 )
2019
4
Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. ( 30450634 )
2019
5
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. ( 30188408 )
2019
6
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. ( 29958825 )
2018
7
Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: An unusual triple association. ( 29368941 )
2018
8
Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the PortalA Vein. ( 29351835 )
2018
9
A case of portal vein thrombosis caused by blunt abdominal trauma in a patient with low protein C activity. ( 29923164 )
2018
10
Congenital Thrombophilia in Patients With Superior Mesenteric Venous Thrombosis or Portal Vein Thrombosis. ( 29747524 )
2018
11
Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. ( 29792748 )
2018
12
Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts. ( 29377486 )
2018
13
The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. ( 29451181 )
2018
14
Portal vein thrombosis: What surgeons need to know. ( 29963409 )
2018
15
Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. ( 29886103 )
2018
16
Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. ( 29973997 )
2018
17
Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy. ( 29272568 )
2018
18
Portal vein thrombosis: yes or no on anticoagulation therapy. ( 29432256 )
2018
19
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. ( 29327075 )
2018
20
Portal vein thrombosis after donor liver biopsy: Case report. ( 29692529 )
2018
21
Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia-related portal vein thrombosis. ( 29372608 )
2018
22
Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis. ( 29849584 )
2018
23
Acute portal vein thrombosis after hepatectomy in a patient with hepatolithiasis: A case report and review of the literature. ( 29924030 )
2018
24
Treatment of portal vein thrombosis in cirrhosis: is it really needed? ( 29979322 )
2018
25
Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. ( 29329568 )
2018
26
Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. ( 29407630 )
2018
27
Transient portal vein thrombosis in liver cirrhosis. ( 29871683 )
2018
28
Obesity is not associated with an increased risk of portal vein thrombosis in cirrhotic patients. ( 29910857 )
2018
29
Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. ( 29890295 )
2018
30
Timing of the Treatment of Portal Vein Thrombosis in Patients with Cirrhosis: A German Hepatologist's Perspective. ( 29607298 )
2018
31
The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. ( 29178991 )
2018
32
Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. ( 29916054 )
2018
33
Anticoagulation treatment of portal vein thrombosis in a patient with cirrhosis awaiting liver transplantation: A case report. ( 29952969 )
2018
34
Adult Living Donor Liver Transplantation for Patients With Portal Vein Thrombosis: A Single-center Experience. ( 29796412 )
2018
35
Portal Vein Thrombosis: A Rare Complication of Nephrotic Syndrome. ( 29962677 )
2018
36
D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. ( 30323642 )
2018
37
Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis. ( 30049580 )
2018
38
Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers. ( 30107378 )
2018
39
Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. ( 30202445 )
2018
40
Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis. ( 29050501 )
2018
41
Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: A US Hepatologist's Perspective. ( 29607296 )
2018
42
Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. ( 29607297 )
2018
43
Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. ( 28342265 )
2018
44
Impact of Non-Malignant Portal Vein Thrombosis in Transplant Recipients with Nonalcoholic Steatohepatitis. ( 30091296 )
2018
45
Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis. ( 29462027 )
2018
46
Acute portal vein thrombosis in a 59-year-old male with JAK2 V617F mutation. ( 30258517 )
2018
47
Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort. ( 30307066 )
2018
48
Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture. ( 30356984 )
2018
49
Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. ( 30357003 )
2018
50
Intraoperative balloon angioplasty for chronic portal vein thrombosis in Liver Transplantation. ( 30380200 )
2018
Sources

Variations for Portal Vein Thrombosis

About this section
Sources

Expression for Portal Vein Thrombosis

About this section
Search GEO for disease gene expression data for Portal Vein Thrombosis.
Sources

Pathways for Portal Vein Thrombosis

About this section

Pathways related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Collagen chain trimerization 66
Show member pathways
 12.39 F2 F5 F7 SERPINC1
2
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.3 APOH F2 F5 F7 JAK2 SELP
3
Selenium Micronutrient Network 1
Show member pathways
 11.89 F2 F7 MTHFR SERPINE1
4
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.76 F2 F5 F7 SERPINC1 SERPINE1
5
Complement and coagulation cascades 1 37
11.5 F2 F5 F7 SERPINC1 SERPINE1
6
FOXA2 and FOXA3 transcription factor networks 1
11.08 AFP F2
7
Immune response_IL-12 signaling pathway 22
Show member pathways
 10.87 JAK2 SELP
8
Warfarin Pathway, Pharmacodynamics 61
10.5 F2 F7
Sources

GO Terms for Portal Vein Thrombosis

About this section

Cellular components related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 AFP APOH F2 F5 F7 SERPINC1
2 collagen-containing extracellular matrix GO:0062023 9.43 APOH SERPINC1 SERPINE1
3 endoplasmic reticulum lumen GO:0005788 9.35 AFP F2 F5 F7 SERPINC1
4 extracellular space GO:0005615 9.23 AFP APOH F2 F5 F7 SELP

Biological processes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.71 AFP F2 F5 SERPINC1
2 ER to Golgi vesicle-mediated transport GO:0006888 9.69 F2 F5 F7
3 platelet degranulation GO:0002576 9.67 APOH F5 SELP SERPINE1
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 F2 JAK2 SELP
5 blood coagulation GO:0007596 9.55 F2 F5 F7 JAK2 SERPINC1
6 blood circulation GO:0008015 9.52 F5 MTHFR
7 regulation of blood coagulation GO:0030193 9.5 APOH F2 SERPINC1
8 fibrinolysis GO:0042730 9.49 F2 SERPINE1
9 blood coagulation, intrinsic pathway GO:0007597 9.48 APOH F2
10 negative regulation of blood coagulation GO:0030195 9.46 APOH SERPINE1
11 negative regulation of fibrinolysis GO:0051918 9.43 APOH F2 SERPINE1
12 hemostasis GO:0007599 9.26 F2 F5 F7 SERPINC1
13 positive regulation of blood coagulation GO:0030194 8.92 APOH F2 F7 SERPINE1

Molecular functions related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 F2 F7 JAK2 SERPINE1
2 lipopolysaccharide binding GO:0001530 9.16 F2 SELP
3 heparin binding GO:0008201 8.92 APOH F2 SELP SERPINC1
Sources

Sources for Portal Vein Thrombosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....